Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SUMMIT

Financiado

Cerrado

SUrrogate markers for vascular Micro and Macrovascular hard endpoints for Innov...

SUrrogate markers for vascular Micro and Macrovascular hard endpoints for Innovative diabetes Tools Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can nei... ver más

31/10/2015

BII GMBH

35M€

Presupuesto del proyecto: 35M€

Líder del proyecto

BOEHRINGER INGELHEIM INTERNATIONALGMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 26 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-10-31 No tenemos la información de la convocatoria

0% 42% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

26 Participantes

BII GMBH

0.00€ | Lider

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

UEDIN

N.D. | Participante

UCSC

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SUMMIT SUrrogate markers for vascular Micro- and Macrovascular hard... 35M€ Cerrado

EULAMDIMA Joint European and Latin American Research Network on Diabet... 452K€ Cerrado

RECOGNISED Retinal and cognitive dysfunction in type 2 diabetes unrave... 6M€ Cerrado

Hypo-RESOLVE Hypoglycaemia REdefining SOLutions for better liVEs 27M€ Cerrado

EUIN2013-51220 EUROPEAN CONSORTIUM FOR RISK STRATIFICATION AND MANAGEMENT O... 23K€ Cerrado

PROMINENT Personalised Medicine in Diabetic Chronic Disease Management 3M€ Cerrado

Líder del proyecto

BOEHRINGER INGELHEIM INTERNATIONALGMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 35M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Worldwide prevalence figures estimate that there will be 246 million diabetic patients in 2007 and 380 million in 2025. Presently, diabetes can neither be prevented nor cured and the disease is associated with devastating chronic complications including coronary heart disease and stroke (macrovascular disease) as well as microvascular disorders leading to damage of the small blood vessels of the kidney (nephropathy), eye(retinopathy) and peripheral nerves (neuropathy). These complications impose an immense burden on the quality of life of the patients and account for more than 10% of health care costs in Europe. Therefore, novel means to prevent these devastating diabetic complications are needed. An important mean in this undertaking would be to develop tools which would make development of novel drugs for prevention of complications more feasible. The SUMMIT consortium brings together European key leaders in the field of diabetes research; scientists with a deep insight into genetics, biomarker discovery, development of novel imaging assays for assessing progression of complications, novel animal models for chronic diabetic complications, in silico models to predict development of complications and response to novel treatments. Given the track record of this unique group of scientists, it can be anticipated that they will not only during the 6-year period discover novel surrogate markers for vascular complications in diabetes, but also validate them in large representative cohorts aiming at prevention of the devastating complications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores